logo-loader

Circassia to hit sales target as cash position improves

Published: 02:54 09 Jan 2020 EST

Circassia Pharmaceuticals PLC -
Duaklir is a treatment for COPD sufferers

Inhaled drug specialist Circassia PLC’s (LON:CIR) revenues in 2019 were in the middle of its guidance of £60-65mln while cash at the year-end was higher than expected.

Sales in the middle of the range represent an annual increase of about 31% and include a modest contribution from Duaklir, which was launched in the US at the end of October. 

Timing of inventory and rebate payments boosted the cash position to £27mln, but even without these there was a significant improvement in net cash flow in the second half said the AIM-listed group.

Circassia also announced the appointment of Michael Roller as chief financial officer to replace Julien Cotta, who has stepped down after eight years in the role.

Roller previously held the finance director roles at Corin Group and Bioquell, where he worked with Circassia’s executive chairman Ian Johnson.

Rush Rare Metals Advances Two Key Projects: Uranium in Wyoming and Niobium...

Rush Rare Metals CEO Peter Smith joined Steve Darling from Proactive to share news about the mineral exploration company's focus on its Boxi Property in Quebec and the Copper Mountain Project in Wyoming. The company recently announced the staking of the Knob claims in Wyoming, comprising 52...

23 minutes ago